AIM
DNLI icon

AIA Investment Management’s Denali Therapeutics DNLI Stock Holding History

AIA Investment Management’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		$1.06M Buy
29,678
+4,330
+17% +$130K 0.24% 75
2020
Q2 		$613K Sell
25,348
-503
-2% -$11.8K 0.14% 73
2020
Q1 		$453K Buy
+25,851
New +$539K 0.09% 68

Other funds holding DNLI

CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AIA Investment Management's DNLI Position: Q3 2020 in Review

AIA Investment Management increased its Denali Therapeutics (DNLI) stake by 17% in Q3 2020, buying an estimated $130K and bringing the position to 29,678 shares worth $1.06M. The position accounts for 0.24% of the portfolio, ranked #75.

AIA Investment Management first reported a position in DNLI in Q1 2020 and has held it in 3 quarters since. 170 funds tracked by Wall St. Rank hold DNLI as of Q3 2020.

  • AIA Investment Management held 29,678 shares of Denali Therapeutics worth $1.06M as of Q3 2020.
  • AIA Investment Management bought 4,330 Denali Therapeutics shares in Q3 2020, an estimated $130K.
  • Denali Therapeutics made up 0.24% of AIA Investment Management's portfolio in Q3 2020, its #75 holding.
  • AIA Investment Management first reported a position in Denali Therapeutics in Q1 2020 and has held it in 3 quarters since.
  • 170 funds tracked by Wall St. Rank held Denali Therapeutics as of Q3 2020.

Based on AIA Investment Management's 13F filing for Q3 2020, filed 16 Nov 2020.